SAN DIEGO, Nov. 21, 2017 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced a change to the company's presentation time at the Evercore ISI Biopharma Catalyst/Deep Dive Conference in Boston.
Marty Duvall, chief executive officer, will now present at 1:35 p.m. ET on Wednesday, November 29. The live audio webcast from the conference and subsequent replay may be accessed by visiting Tocagen's website. The webcast will be available shortly after conclusion of the presentation and archived on the company's website for 90 days following the presentation.
Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient's immune system against their own cancer. Tocagen is developing its lead investigational product candidate, Toca 511 & Toca FC, initially for the treatment of recurrent high-grade glioma (HGG), a disease with significant unmet medical need. The U.S. Food and Drug Administration (FDA) has granted Toca 511 & Toca FC Breakthrough Therapy Designation for the treatment of recurrent HGG and the European Medicines Agency (EMA) has granted Toca 511 PRIME (PRIority MEdicines) designation for the treatment of HGG.
View original content with multimedia:http://www.prnewswire.com/news-releases/tocagen-announces-time-change-for-presentation-at-evercore-isi-biopharma-catalystdeep-dive-conference-300559988.html
SOURCE Tocagen Inc.
Monica May, Canale Communications, (619) 849-5383, email@example.com; Investor Contact: Elizabeth Broder, The Trout Group, (646) 378-2945, firstname.lastname@example.org